Breakthroughs in hepatitis C research: from discovery to cure
MP Manns, B Maasoumy - Nature reviews Gastroenterology & …, 2022 - nature.com
In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
O Falade-Nwulia, C Suarez-Cuervo… - Annals of internal …, 2017 - acpjournals.org
Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …
EASL recommendations on treatment of hepatitis C 2016
European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …
[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015
European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection
S Zeuzem, GR Foster, S Wang… - … England Journal of …, 2018 - Mass Medical Soc
Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with
pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety …
pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety …
Mitochondrial dysfunction in diabetic kidney disease
Globally, diabetes is the leading cause of chronic kidney disease and end-stage renal
disease, which are major risk factors for cardiovascular disease and death. Despite this …
disease, which are major risk factors for cardiovascular disease and death. Despite this …
Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens
JM Pawlotsky - Gastroenterology, 2016 - Elsevier
Treatment of hepatitis C virus (HCV) infection has progressed considerably with the
approval of interferon-free, direct-acting antiviral (DAA)-based combination therapies …
approval of interferon-free, direct-acting antiviral (DAA)-based combination therapies …
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared …
[BOOK][B] Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15
World Health Organization - 2015 - books.google.com
These are the first World Health Organization (WHO) guidelines for the prevention care and
treatment of persons living with CHB infection and complement similar recent published …
treatment of persons living with CHB infection and complement similar recent published …